加载中
NASDAQHealthcareBiotechnology
最新数据
US$30.39
−US$1.23 · -3.89%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
收盘时
US$30.39
−US$1.23 · -3.89%
盘后
US$30.39
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$30.39
52周区间
当前US$30.39
盘中时间采用ET。市场数据可能有所延迟。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$30.39
52周区间
当前US$30.39
| 项目（USD） | 2025财年 |
|---|---|
| 研究与开发 | 5963.2万 USD |
| 销售、一般及管理费用 | 1048.7万 USD |
| 营业费用 | 7011.9万 USD |
| 利息收入 | 197.4万 USD |
| 折旧和摊销 | 30.4万 USD |
| 营业利润 | −7011.9万 USD |
| 净利润 | −6391.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$51.40
上涨空间 69.13%评级样本有限，仅3项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2540.5万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1616万0.02%787.4亿 USD0.19%US$277.88-0.38%
State Street SPDR S&P Biotech ETFXBI1602.81万0.16%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF940.72万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO349.91万0.03%139.17亿 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA287.58万0.01%218.24亿 USD0.03%US$32.66-0.40%
Fidelity Fundamental Small-Mid Cap ETFFFSM166.47万0.10%14.4亿 USD0.43%US$34.02-0.32%
T. Rowe Price Small-Mid Cap ETFTMSL121.72万0.04%30.87亿 USD0.55%US$40.99-0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMT. Rowe Price Small-Mid Cap ETFTMSLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
